WO2002028355A3 - Methods and compositions for enhancing angiogenesis - Google Patents
Methods and compositions for enhancing angiogenesis Download PDFInfo
- Publication number
- WO2002028355A3 WO2002028355A3 PCT/US2001/042375 US0142375W WO0228355A3 WO 2002028355 A3 WO2002028355 A3 WO 2002028355A3 US 0142375 W US0142375 W US 0142375W WO 0228355 A3 WO0228355 A3 WO 0228355A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiogenesis
- methods
- enhancing angiogenesis
- enhancing
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/130,337 US20040105857A1 (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
AU1182402A AU1182402A (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
CA002423656A CA2423656A1 (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
JP2002531981A JP2005508831A (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for promoting angiogenesis |
EP01979907A EP1363653A4 (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
AU2002211824A AU2002211824B2 (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23773900P | 2000-10-02 | 2000-10-02 | |
US60/237,739 | 2000-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002028355A2 WO2002028355A2 (en) | 2002-04-11 |
WO2002028355A3 true WO2002028355A3 (en) | 2003-09-25 |
Family
ID=22894953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/042375 WO2002028355A2 (en) | 2000-10-02 | 2001-09-26 | Methods and compositions for enhancing angiogenesis |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040105857A1 (en) |
EP (1) | EP1363653A4 (en) |
JP (1) | JP2005508831A (en) |
AU (2) | AU2002211824B2 (en) |
CA (1) | CA2423656A1 (en) |
WO (1) | WO2002028355A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2441461T1 (en) | 2005-11-07 | 2014-09-30 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
US20110076255A1 (en) | 2005-11-07 | 2011-03-31 | Pecora Andrew L | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
GB0703652D0 (en) * | 2007-02-26 | 2007-04-04 | Univ Bradford | Method for the allosteric modulation of beta1 integrin |
BRPI0920976A2 (en) | 2008-12-03 | 2015-08-18 | Amorcyte Inc | Compositions that improve infusion area perfusion and vascular lesion restoration methods. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313265B1 (en) * | 1995-07-24 | 2001-11-06 | The Scripps Research Institute | Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use |
WO2001051523A2 (en) * | 2000-01-07 | 2001-07-19 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
-
2001
- 2001-09-26 US US10/130,337 patent/US20040105857A1/en not_active Abandoned
- 2001-09-26 AU AU2002211824A patent/AU2002211824B2/en not_active Ceased
- 2001-09-26 AU AU1182402A patent/AU1182402A/en active Pending
- 2001-09-26 EP EP01979907A patent/EP1363653A4/en not_active Ceased
- 2001-09-26 JP JP2002531981A patent/JP2005508831A/en not_active Withdrawn
- 2001-09-26 WO PCT/US2001/042375 patent/WO2002028355A2/en active Search and Examination
- 2001-09-26 CA CA002423656A patent/CA2423656A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
EP1363653A4 (en) | 2004-12-22 |
JP2005508831A (en) | 2005-04-07 |
AU1182402A (en) | 2002-04-15 |
AU2002211824B2 (en) | 2006-11-02 |
WO2002028355A2 (en) | 2002-04-11 |
US20040105857A1 (en) | 2004-06-03 |
EP1363653A2 (en) | 2003-11-26 |
CA2423656A1 (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002024909A3 (en) | Receptor nucleic acids and polypeptides | |
EP1336410A4 (en) | Protein injection preparations | |
WO2001075087A8 (en) | Subtilisin variants | |
WO2001059066A3 (en) | Protein design automation for protein libraries | |
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
WO2002006316A3 (en) | Alpha-msh related compounds and methods of use | |
EE200200444A (en) | Method for In vivo Suppression of Autologous Beta-Amyloid Resin, an Amyloidogenic Polypeptide Analog, a Nucleic Acid Fragment Encoding It, and Use for the Preparation of an Immunogenic Composition | |
AU2001255196A1 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
WO2001090182A3 (en) | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
AU1325102A (en) | Protein scaffolds for antibody mimics and other binding proteins | |
WO2002032374A3 (en) | Methods for treating il-18 mediated disorders | |
WO2002085903A3 (en) | Amyloid plaque aggregation inhibitors and diagnostic imaging agents | |
WO2001073059A3 (en) | 38692 and 21117: dual specificity phosphatase molecules and uses therefor | |
AU2001290315A1 (en) | Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding | |
AU2001286730A1 (en) | An iap binding peptide or polypeptide and methods of using the same | |
WO2008020335A3 (en) | Immunogenic compositions for streptococcus agalactiae | |
WO2001068697A3 (en) | Methods and compositions for immunoregulation | |
WO2002028355A3 (en) | Methods and compositions for enhancing angiogenesis | |
IL138946A0 (en) | Method for the identification of peptides and proteins | |
WO2001058470A3 (en) | Methods for enhancing the bioavailability of a drug | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
WO2005011571A3 (en) | Hepatitis virus core proteins as vaccine platforms and methods of use thereof | |
EP1276757A4 (en) | ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2423656 Country of ref document: CA Ref document number: 10130337 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002531981 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002211824 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001979907 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001979907 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |